Ignyta: RXDX-101 Interim Data Shows Promising Signs Of Antitumor Activity

(RTTNews) - Ignyta Inc. (RXDX) announced interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications. The company said the interim data showed no dose-limiting toxicities and very promising signs of antitumor activity.

Jonathan Lim, CEO of Ignyta, said; "We saw partial responses in patients with each of TrkA, ROS1 and ALK alterations, as well as in three different tumor types, despite the fact that patients dosed with the present intermittent dosing schedule received drug for only 12 days out of each 28 day cycle. RXDX-101 treatment in this study has achieved a landmark milestone in oncology drug development, as the patient with TrkA positive metastatic colorectal cancer represents the first reported case of a patient with a TrkA positive tumor to be treated with a TrkA inhibitor. Most importantly, she showed clinical improvement and achieved a partial response within the first month of treatment with RXDX-101 after having failed first-, second- and third-line chemo- and targeted therapies."